Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Midwest Biomedical Research Foundation

Neither a doctor nor a teaching hospital

Research payments

$1,433,518

174 payments

Through program year 2025, Midwest Biomedical Research Foundation is reported as receiving $1,433,518 in research payments, across 174 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $401,750 16
2024 Research $205,984 21
2023 Research $179,246 15
2022 Research $51,359 15
2021 Research $190,045 37
2020 Research $196,059 32
2019 Research $209,074 38

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $316,129 9 payments
  2. Intercept Pharmaceuticals, Inc. $208,726 53 payments
  3. AstraZeneca Pharmaceuticals LP $185,716 11 payments
  4. AbbVie, Inc. $138,167 6 payments
  5. Olympus Corporation of the Americas $119,741 5 payments
  6. Pfizer Inc. $94,696 7 payments
  7. Intercept Pharma Europe Ltd. $80,536 7 payments
  8. Kowa Research Institute, Inc. $50,944 7 payments
  9. GlaxoSmithKline, LLC. $41,556 11 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $36,764 11 payments
Studies the money was for Research payments · program years 2019–2025
  1. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $180,786 3 payments
  2. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $132,002 25 payments
  3. A Randomized Doubleblind Phase 3 Study of Avelumab in Combination With Standard of Care Chemoradiotherapy Cisplatin Plus Definitive Radiation Therapy Versus Standard of Care Chemoradiotherapy in the Frontline Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck $94,696 7 payments
  4. A25-547;Venclexta;Bottle: ABT-199 100mg Film-coated Tablet 120 Tablets $78,090 1 payment
  5. A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension $76,517 1 payment
  6. 1011866 $70,693 17 payments
  7. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $68,052 2 payments
  8. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $67,842 11 payments
  9. A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $62,343 1 payment
  10. Veterans Affairs (VA) Lipid Optimization Quality Improvement Program (VALOR-QI) in Veterans with Atherosclerotic Cardiovascular Disease (ASCVD) $62,166 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record